{"nctId":"NCT03214380","briefTitle":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","startDateStruct":{"date":"2017-07-14","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":933,"armGroups":[{"label":"LY900014","type":"EXPERIMENTAL","interventionNames":["Drug: LY900014","Drug: Insulin Glargine","Drug: Insulin Degludec","Drug: Metformin","Drug: SGLT2 inhibitor"]},{"label":"Insulin Lispro (Humalog)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin Lispro","Drug: Insulin Glargine","Drug: Insulin Degludec","Drug: Metformin","Drug: SGLT2 inhibitor"]},{"label":"LY900014 Maximum Extended Enrollment (MEE)","type":"EXPERIMENTAL","interventionNames":["Drug: LY900014","Drug: Insulin Glargine","Drug: Insulin Degludec","Drug: Metformin","Drug: SGLT2 inhibitor"]},{"label":"Insulin Lispro (Humalog) MEE","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin Lispro","Drug: Insulin Glargine","Drug: Insulin Degludec","Drug: Metformin","Drug: SGLT2 inhibitor"]}],"interventions":[{"name":"LY900014","otherNames":["Ultra-Rapid Lispro"]},{"name":"Insulin Lispro","otherNames":["Humalog"]},{"name":"Insulin Glargine","otherNames":[]},{"name":"Insulin Degludec","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"SGLT2 inhibitor","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have been diagnosed (clinically) with T2D, based on the World Health Organization (WHO) classification for at least 1 year prior to screening.\n* Have been treated for at least 90 days prior to screening with:\n\n  * Basal insulin (insulin glargine U-100 \\[Basaglar/Abasaglar or LANTUS\\] or U-300, insulin detemir, insulin degludec U-100 or U-200, or neutral protamine Hagedorn \\[NPH\\] insulin) in combination with at least 1 prandial injection of bolus insulin (insulin lispro U-100 or U-200, insulin aspart, insulin glulisine, or regular insulin) Or\n  * Premixed analog or human insulin regimens with any basal and bolus insulin combination injected at least twice daily\n* Participants may be treated with up to 3 of the following oral antihyperglycemic medications (OAMs) in accordance with local regulations:\n\n  * Metformin\n  * Dipeptidyl peptidase-4 (DPP-4) inhibitor\n  * Sodium glucose cotransporter 2 (SGLT2) inhibitor\n  * Sulfonylurea\n  * Meglitinide\n  * Alpha-glucoside inhibitor\n* Have an HbA1c value between ≥7.0 and ≤10.0%, according to the central laboratory at the time of screening.\n* Have a body mass index (BMI) of ≤45.0 kilograms per meter squared at screening.\n\nExclusion Criteria:\n\n* Have been diagnosed, at any time, with type 1 diabetes (T1D) or Latent Autoimmune Diabetes in Adults.\n* Have hypoglycemia unawareness as judged by the investigator.\n* Have had any episode of severe hypoglycemia within the 6 months prior to screening.\n* Have had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the 6 months prior to screening.\n* Have used thiazolidinediones, Glucagon-Like Peptide 1 (GLP-1) receptor agonist, or pramlintide within 90 days prior to screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26","description":"Change from baseline in HbA1c was performed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"0.042"},{"groupId":"OG001","value":"-0.38","spread":"0.042"}]}]}]},{"type":"SECONDARY","title":"1-hour Postprandial Glucose (PPG) Excursion During Mixed-Meal Tolerance Test (MMTT) Efficacy Estimand","description":"1-hour PPG excursion during MMTT uses the analysis of covariance (ANCOVA) model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum) and treatment as fixed effects and baseline as a covariate. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.9","spread":"3.60"},{"groupId":"OG001","value":"63.1","spread":"3.60"}]}]}]},{"type":"SECONDARY","title":"2-hour PPG Excursion During MMTT Efficacy Estimand","description":"2-hour PPG excursion during MMTT uses the ANCOVA model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum) and treatment as fixed effects and baseline as a covariate. The efficacy estimand included participant data when baseline and at least one post-baseline measurement were available prior to permanent discontinuation of study drug.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":"4.50"},{"groupId":"OG001","value":"80.4","spread":"4.50"}]}]}]},{"type":"SECONDARY","title":"Rate of Severe Hypoglycemia","description":"Rate of severe hypoglycemia events per 100 years during a defined period was calculated by total number of severe hypoglycemia episodes within the period divided by the cumulative days on treatment from all participants within a treatment group \\*36525. Severe hypoglycemia is defined as an event requiring assistance of another person to administer carbohydrate, glucagon, or other resuscitative actions. During these episodes, the participant has an altered mental status and cannot assist in his or her own care, or may be semiconscious or unconscious, or experience com with or without seizures, and may require parenteral therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.19","spread":null},{"groupId":"OG001","value":"2.44","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Documented Symptomatic Hypoglycemia","description":"Documented symptomatic hypoglycemia is an event during which typical symptoms of hypoglycemia are accompanied by blood glucose (BG) of \\<54 mg/dL \\[3.0 millimole per liter (mmol/L)\\]. The rate of documented symptomatic hypoglycemia was estimated by negative binomial model: number of episodes = treatment with log (treatment exposure in days/365.25) as an offset variable.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.164"},{"groupId":"OG001","value":"2.21","spread":"0.318"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 1,5-Anhydroglucitol (1,5-AG) at Week 26","description":"Change from baseline in 1,5-AG was analyzed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The analysis included data collected prior to permanent discontinuation of study drug.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":"0.234"},{"groupId":"OG001","value":"1.99","spread":"0.235"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 10-Point Self-Monitoring Blood Glucose (SMBG) Values at Week 26","description":"Change from baseline in 10-point SMBG values was analyzed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The efficacy estimand included participant data when baseline and at least one post-baseline measurement prior to permanent discontinuation of study drug.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"2.72"},{"groupId":"OG001","value":"1.5","spread":"2.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"3.44"},{"groupId":"OG001","value":"-14.1","spread":"3.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"3.38"},{"groupId":"OG001","value":"-14.9","spread":"3.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"2.83"},{"groupId":"OG001","value":"4.1","spread":"2.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"3.48"},{"groupId":"OG001","value":"-2.0","spread":"3.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"3.28"},{"groupId":"OG001","value":"-6.5","spread":"3.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"3.38"},{"groupId":"OG001","value":"10.1","spread":"3.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"3.24"},{"groupId":"OG001","value":"-3.0","spread":"3.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"3.68"},{"groupId":"OG001","value":"-2.1","spread":"3.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"4.00"},{"groupId":"OG001","value":"-2.2","spread":"4.02"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Insulin Dose at Week 26","description":"Change from baseline in insulin dose was analyzed using mixed model repeated measures (MMRM) including fixed class effects of treatment, strata (pooled country, type of basal insulin, HbA1c stratum and number of prandial doses at study entry), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline value. The analysis included data prior to permanent discontinuation of study drug.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"0.82"},{"groupId":"OG001","value":"4.6","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"1.41"},{"groupId":"OG001","value":"12.0","spread":"1.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"1.93"},{"groupId":"OG001","value":"17.3","spread":"1.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Regimen Inconvenience Domain Score at Week 26","description":"ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data presented are the transformed overall score on a scale of 0-100, where higher scores indicate better treatment satisfaction.\n\nChange from baseline in ITSQ regimen inconvenience domain score was calculated using the ANCOVA model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum), and treatment as fixed effects and baseline as covariate. The analysis included data prior to permanent discontinuation of study drug.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.36"},{"groupId":"OG001","value":"-2.4","spread":"1.37"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in ITSQ Lifestyle Flexibility Domain Score at Week 26","description":"ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Inconvenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data presented are the transformed overall score on a scale of 0-100, where higher scores indicate better treatment satisfaction.\n\nChange from baseline in ITSQ lifestyle flexibility domain score was calculated using the ANCOVA model with strata (pooled country, type of basal insulin, number of prandial doses at study entry, and HbA1c stratum), and treatment as fixed effects and baseline as covariate. The analysis included data prior to permanent discontinuation of study drug.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.60"},{"groupId":"OG001","value":"0.2","spread":"1.60"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With HbA1c <7%","description":"Number of participants with HbA1c \\<7% at Week 26.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"184","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":750},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diarrhoea"]}}}